In the trial CNS involvement was an exclusion criteria from treatment (this is standard in clinical trials as CNS patients almost never respond to treatment). To allow the patients to be treated with Bisantrene they had to get approval from the IRB (Institutional Review Board - basically the ethics committee) to allow the patients into the trial. Just another example of how difficult to treat the patients were in this trial and how outstanding the response was. I continue to go on about this, but the patients in the first Israeli trial were the patients that had exhausted all treatment options and in most trials never respond.
I have nothing more I can add in regards the response of the patients with CNS involvement other what is in the published paper.
There is not a lot about the EMD AML mouse model I can add at this stage (there will be more later(, but yes CNS involvement and treatment will be part of what is checked.
Pillar 1 - FTO (new thread), page-872
-
- There are more pages in this discussion • 2,120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.015(0.95%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.63 | $1.56 | $160.1K | 100.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 222 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |